Clinical Significance of bcr-abl Gene Rearrangement Detected by the Polymerase Chain Reaction After Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia

References

• Saiki R. K., Scharf S. J., Faloona F. A. Enzymatic amplification of beta globin genomic sequences and restriction site analysis for diagnosis of sickle cell anaemia. Science 1985; 230: 1350–1354
   PubMed Web of Science ®Google Scholar
• Mullis K. B., Faloona F. A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods in Enzymology 1987; 155: 335–350
   PubMed Web of Science ®Google Scholar
• Castaigne S., Balitrand N., de The H., et al. A PML retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992; 79: 3110–3115
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A. S., Woo S. D., et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280
   PubMed Web of Science ®Google Scholar
• Loh E. Y., Elliot J. F., Cwirla S., et al. Polymerase chain reaction with single sided specificity: analysis of T cell receptor delta chain. Science 1989; 243: 217–220
   PubMed Web of Science ®Google Scholar
• Fialkow P. J., Jacobson R. J., Papayannopoulou Th. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. American Journal of Medicine 1977; 63: 125–130
   PubMed Web of Science ®Google Scholar
• Martin P. J., Najfeld V., Hansen J. A., et al. Involvement of the B-lymphoid system in chronic myelogenous leukemia. Nature 1980; 287: 49–50
   PubMed Web of Science ®Google Scholar
• Tucker W., Le Bien Hozier J., et al. Origin of chronic myelocytic leukemia in a precursor of pre-B lymphocytes. New England Journal of Medicine 1979; 301: 144–147
   PubMed Web of Science ®Google Scholar
• Jonas D., Luebbert M., Kawasaki E. S., et al. Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. Blood 1992; 79: 1017–1023
   PubMed Web of Science ®Google Scholar
• Bartram C. R., Raghavachar A., Anger B., et al. T lymphocytes lack rearrangement of the bcr gene in Philadelphia chromosome-positive chronic myelocytic leukemia. Blood 1987; 69: 1682–1685
   PubMed Web of Science ®Google Scholar
• Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by Quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Bartram C. R., de Klein A., Hagemeijer A., et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 1983; 306: 277–280
   PubMed Web of Science ®Google Scholar
• Groffen J., Stephenson J. R., Heisterkamp N., et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on Chromosome 22. Cell 1984; 36: 93–99
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Gutterman J. U., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New England Journal of Medicine 1988; 319: 990–998
   PubMed Web of Science ®Google Scholar
• Look A. T. The emerging genetics of acute lymphoblastic leukemia: clinical and biologic implications. Semin. Oncol 1985; 12: 92–104
   PubMed Web of Science ®Google Scholar
• Whang-Peng J., Henderson R. S., Knutsen T., et al. Cytogenetic studies in acute myelocytic leukemia with special emphasis in the occurrence of the Ph1 chromosome. Blood 1970; 36: 448–457
   PubMed Web of Science ®Google Scholar
• Bernards A., Rubin Ch. M., Westbrook C. A., et al. The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Molecular and Cellular Biology 1987; 7: 3231–3236
   PubMed Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., et al. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986; 47: 277–284
   PubMed Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550–554
   PubMed Web of Science ®Google Scholar
• Konopka J. B., Watanabe S. M., Witte O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035–1042
   PubMed Web of Science ®Google Scholar
• Konopka J. B., Witte O. N. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered gene products. Molecular and Cellular Biology 1985; 5: 3116–3123
   PubMed Web of Science ®Google Scholar
• Kelliher M. A., McLaughlin J., Witte O., et al. Induction of chronic myelogeneous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Science 1990; 87: 6649–6653
   PubMed Web of Science ®Google Scholar
• Daley G. Q., van Etter R. A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 BCR/ABL gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Cleary M. L., Chao J., Wanke R., et al. Immunoglobu-lin gene rearrangement as a diagnostic criterion of B cell lymphoma. Proc. Nail. Acad. Science 1984; 81: 593–597
   PubMed Web of Science ®Google Scholar
• Pezzella F., Gatter K. C., Mason D. Y. Detection of 14;18 chromosomal translocation in paraffin embedded lymphoma tissue. Lancet 1989; 1: 779–780
   PubMed Web of Science ®Google Scholar
• Li W. J., Smith L. A., Rabat K. G., et al. Differential effects of tumor promotors on P210 bcr-abl expression. Hematol. Pathol. 1989; 3: 113–123
   PubMedGoogle Scholar
• Thompson J. D., Brodsky I., Yunis J. J. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 1992; 79: 1629–1635
   PubMed Web of Science ®Google Scholar
• Janssen J. W. G., Morgan G., Martiat Ph., et al. False-positive results with PCR to detect leukemia-specific transcript. Lancet 1990; 335: 1037–1038
   PubMed Web of Science ®Google Scholar
• Kwok S., Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237–238
   PubMed Web of Science ®Google Scholar
• Martens A. C. M., Schultz F. W., Hagenbeek A. Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood 1987; 70: 1073–1078
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Gale R. P., Horowitz M. M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann. Intern. Med. 1986; 108: 806–814
   Web of Science ®Google Scholar
• Thomas E. D., Clift R. A. Indications for bone marrow transplantation in chronic myelogenous leukemia. Blood 1989; 73: 861–864
   PubMed Web of Science ®Google Scholar
• Martin P. J., Clift R. A., Fisher L. D., et al. HLA identical marrow transplantation during accelerated phase chronic myelogenous leukemia. Blood 1988; 72: 1978–1984
   PubMed Web of Science ®Google Scholar
• Advisory committee of the international bone marrow transplant registry. Report from the international bone marrow transplant registry. Bone marrow transplantation 1989; 4: 221–228
   PubMed Web of Science ®Google Scholar
• Thomas E. D., Clift R. A., Fefer A., et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Annals of Internal Medicine 1986; 104: 155–163
   PubMed Web of Science ®Google Scholar
• Cunningham I., Gee T., Dowling M., et al. Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 Protocol). Blood 1979; 53: 375–395
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Vellekoop L., McCredie K. B., et al. Intensive combination chemotherapy (ROAP 10) and sple-nectomy in the management of chronic myelogenous leukemia. Journal of Clinical Oncology 1985; 3(2)192–200
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., et al. Interferon alpha produces sustained cutogenetic responses in chronic myelogenous leukemia. Annals of Internal Medicine 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Arthur C. K., Apperley J. F., Guo A. P., et al. Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. Blood 1988; 71: 1179–1186
   PubMed Web of Science ®Google Scholar
• Zaccaria A., Rosti G., Sessarego M., et al. Relapse after allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia: cytogenetic analysis of 24 patients. Bone Marrow Transplantation 1988; 3: 413–423
   PubMed Web of Science ®Google Scholar
• Apperley J. F., Rassool F., Parreira A., et al. Philadelphia-positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia. American Journal of Hematology 1986; 22: 199–204
   PubMed Web of Science ®Google Scholar
• Opalka B., Kloke O., Bartram C. R., et al. Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia. Lancet 1989; 1: 1334
   PubMed Web of Science ®Google Scholar
• Opalka B., Wandl U. B., Becher R., et al. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma. Blood 1991; 78: 2188–2193
   PubMed Web of Science ®Google Scholar
• Gabert J., Thuret I., Lafage M., et al. Detection of minimal residual bcr-abl translocation by polymerase chain reaction in chronic myeloid leukaemia after bone marrow transplantation. Lancet 1989; 335: 1125–1128
   Google Scholar
• Bartram C., Janssen J. W., Schmidberger M., et al. Minimal residual leukaemia in chronic myeloid leukaemia patients after T-cell depleted bone marrow transplantation. Lancet 1989; 1: 1260
   PubMed Web of Science ®Google Scholar
• Pignon J. M., Amselem S., Vidaud M., et al. Frequent detection of minimal residual disease by use of polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. Leukemia 1990; 4: 83–86
   PubMed Web of Science ®Google Scholar
• Martiat P., Maisin D., Phillippe A., et al. Detection of BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers. British Journal of Hematology 1990; 75: 355–358
   PubMed Web of Science ®Google Scholar
• Morgan G. J., Janssen J. W. G., Guo A. P., et al. Polymerase chain reaction for detection of residual leukemia. Lancet 1989; 1: 928–929
   PubMed Web of Science ®Google Scholar
• Delfau M. H., Kerckaert J. P., d'Hooghe M. C., et al. Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction. Leukaemia 1990; 4: 1–5
   PubMed Web of Science ®Google Scholar
• Hughes T. P., Morgan G. J., Martiat P., et al. Detection of residual leukemia after bone marrow transplantation in chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874–878
   PubMed Web of Science ®Google Scholar
• Saglio G., Martinelli G., Guerrasio A., et al. Significance of minimal residual disease detected by PCR in 48 longterm disease free CML patients with after allogeneic BMT. ECCO 6, Florence. 1991, abstract No 1409
   Google Scholar
• Sawyers Ch. L., Timson L., Kawasaki E. S., et al. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc. Natl. Acad. Science 1990; 87: 563–567
   PubMed Web of Science ®Google Scholar
• Delage R., Soiffer R. J., Dear K., et al. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991; 78: 2759–2767
   PubMed Web of Science ®Google Scholar
• Roth M. S., Antin J. H., Ash R., et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992; 79: 276–282
   PubMed Web of Science ®Google Scholar
• Ely P., Miller W. J. Bcr-abl mRNA detection following bone marrow transplantation for chronic myelogenous leukemia. Transplantation 1991; 52: 1023–1028
   PubMed Web of Science ®Google Scholar